The reduction in circulating melatonin level may contribute to the pathogenesis of ovarian cancer: A retrospective study

Journal of Cancer

Volumn 7, Issue 7, 2016, Pages 831-836

  Zhao, Min ^a   Wan, Jiayi ^a   Zeng, Ke ^a   Tong, Mancy ^b   Lee, Arier C ^b   Ding, Jinxin ^c   Chen, Qi ^b,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c FUDAN UNIVERSITY   (China)

Author keywords

Melatonin; Menopause; Ovarian cancer; Season of birth

Indexed keywords

MELATONIN;

ADULT; AGED; ARTICLE; AUTUMN; CANCER INCIDENCE; CARCINOGENESIS; CHILDBIRTH; CLIMACTERIUM; CONTROLLED STUDY; FEMALE; GERM CELL TUMOR; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; PERITONEUM METASTASIS; POSTMENOPAUSE; RETROSPECTIVE STUDY; SEASONAL VARIATION; SEX CORD TUMOR; SPRING; SUMMER; WINTER;

EID: 84982830556     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.14573     Document Type: Article

References (29)

1. Edwards B.K., Brown M.L., Wingo P.A., Howe H.L., Ward E., Ries L.A.G., Schrag D., Jamison P.M., Jemal A., and Wu X.C. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. Journal of the National Cancer Institute, 2005. 97(19): 1407.
2. Reiter R.J., Tamura H., Tan D.X., and Xu X.Y. Melatonin and the circadian system: contributions to successful female reproduction. Fertil Steril, 2014. 102(2): 321-8.
3. Lie J.A., Roessink J., and Kjaerheim K. Breast cancer and night work among Norwegian nurses. Cancer Causes Control, 2006. 17(1): 39-44.
4. Hansen J. Increased breast cancer risk among women who work predominantly at night. Epidemiology, 2001. 12(1): 74-7.
5. Davis S., Mirick D.K., and Stevens R.G. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst, 2001. 93(20): 1557-62.
6. Viswanathan A.N., Hankinson S.E., and Schernhammer E.S. Night shift work and the risk of endometrial cancer. Cancer Res, 2007. 67(21): 10618-22.
7. Rowlands I.J., Weinstein P., Nagle C.M., Spurdle A.B., Webb P.M., Australian National Endometrial Cancer S., and Australian Ovarian Cancer S. Season of birth and risk of endometrial cancer. Asian Pac J Cancer Prev, 2011. 12(5): 1193-6.
8. Tan D.X., Manchester L.C., Liu X., Rosales-Corral S.A., Acuna-Castroviejo D., and Reiter R.J. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin's primary function and evolution in eukaryotes. J Pineal Res, 2013. 54(2): 127-38.
9. Glass J.D. and Knotts L.K. A brain site for the antigonadal action of melatonin in the white-footed mouse (Peromyscus leucopus): involvement of the immunoreactive GnRH neuronal system. Neuroendocrinology, 1987. 46(1): 48-55.
10. Itoh M.T., Ishizuka B., Kudo Y., Fusama S., Amemiya A., and Sumi Y. Detection of melatonin and serotonin N-acetyltransferase and hydroxyindole-O-methyltransferase activities in rat ovary. Mol Cell Endocrinol, 1997. 136(1): 7-13.
11. Hill S.M., Spriggs L.L., Simon M.A., Muraoka H., and Blask D.E. The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett, 1992. 64(3): 249-56.
12. Cos S., Mediavilla M.D., Fernandez R., Gonzalez-Lamuno D., and Sanchez-Barcelo E.J. Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro? J Pineal Res, 2002. 32(2): 90-6.
13. Viswanathan A.N. and Schernhammer E.S. Circulating melatonin and the risk of breast and endometrial cancer in women. Cancer Lett, 2009. 281(1): 1-7.
14. Blask D.E., Sauer L.A., and Dauchy R.T. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem, 2002. 2(2): 113-32.
15. Dauchy R.T., Xiang S., Mao L., Brimer S., Wren M.A., Yuan L., Anbalagan M., Hauch A., Frasch T., Rowan B.G., Blask D.E., and Hill S.M. Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. Cancer Res, 2014. 74(15): 4099-110.
16. Soares J.M., Jr., Simoes M.J., Oshima C.T., Mora O.A., De Lima G.R., and Baracat E.C. Pinealectomy changes rat ovarian interstitial cell morphology and decreases progesterone receptor expression. Gynecol Endocrinol, 2003. 17(2): 115-23.
17. Wurtman R.J., Axelrod J., and Chu E.W. Melatonin, a pineal substance: effect on the rat ovary. Science, 1963. 141(3577): 277-8.
18. Tamura H., Nakamura Y., Korkmaz A., Manchester L.C., Tan D.X., Sugino N., and Reiter R.J. Melatonin and the ovary: physiological and pathophysiological implications. Fertil Steril, 2009. 92(1): 328-43.
19. Grin W. and Grunberger W. A significant correlation between melatonin deficiency and endometrial cancer. Gynecol Obstet Invest, 1998. 45(1): 62-5.
20. Poole E.M., Schernhammer E.S., and Tworoger S.S. Rotating night shift work and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev, 2011. 20(5): 934-8.
21. Chuffa L.G., Fioruci-Fontanelli B.A., Mendes L.O., Favaro W.J., Pinheiro P.F., Martinez M., and Martinez F.E. Characterization of chemically induced ovarian carcinomas in an ethanol-preferring rat model: influence of long-term melatonin treatment. PLoS One, 2013. 8(12): e81676.
22. Lissoni P., Barni S., Mandala M., Ardizzoia A., Paolorossi F., Vaghi M., Longarini R., Malugani F., and Tancini G. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer, 1999. 35(12): 1688-92.
23. Lacey J.V., Jr., Mink P.J., Lubin J.H., Sherman M.E., Troisi R., Hartge P., Schatzkin A., and Schairer C. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA, 2002. 288(3): 334-41.
24. Reffelmann T., Ittermann T., Empen K., Dorr M., and Felix S.B. Is cardiovascular mortality related to the season of birth?: evidence from more than 6 million cardiovascular deaths between 1992 and 2007. J Am Coll Cardiol, 2011. 57(7): 887-8.
25. Doblhammer G. and Vaupel J.W. Lifespan depends on month of birth. Proc Natl Acad Sci U S A, 2001. 98(5): 2934-9.
26. Yuen J., Ekbom A., Trichopoulos D., Hsieh C.C., and Adami H.O. Season of birth and breast cancer risk in Sweden. Br J Cancer, 1994. 70(3): 564-8.
27. Jaldo-Alba F., Munoz-Hoyos A., Molina-Carballo A., Molina-Font J.A., and Acuna-Castroviejo D. Light deprivation increases plasma levels of melatonin during the first 72 h of life in human infants. Acta Endocrinol (Copenh), 1993. 129(5): 442-5.
28. Nogueira L.M., Sampson J.N., Chu L.W., Yu K., Andriole G., Church T., Stanczyk F.Z., Koshiol J., and Hsing A.W. Individual variations in serum melatonin levels through time: implications for epidemiologic studies. PLoS One, 2013. 8(12): e83208.
29. Hsing A.W., Meyer T.E., Niwa S., Quraishi S.M., and Chu L.W. Measuring serum melatonin in epidemiologic studies. Cancer Epidemiol Biomarkers Prev, 2010. 19(4): 932-7.